Although progress in understanding the clinical types and patterns of Parkinson’s disease (PD) progression have been made using clinical, genetic and transcriptomic data 1,2,3, there remains a lack of ...

Acquiring a sufficiently powered cohort of control samples matched to a case sample can be time-consuming or, in some cases, impossible. Accordingly, an ability to leverage genetic data from control ...